Dave Maki - Profile and Investment Details

Investor Profile

Dave Maki is a Venture Capital, Investor based in United States with a diverse investment portfolio that includes companies such as Constellation Pharmaceuticals, Cero Therapeutics, Encoded Therapeutics, Siluria Technologies, Nuvation Bio, Tessera Therapeutics, Sana Biotechnology, Vividion Therapeutics, Arete Therapeutics, Receptos, Pulmatrix, UNITY Biotechnology, Omniome, Vir Biotechnology, BlackThorn Therapeutics, Millendo TherapeuticsDiCE Molecules, Kythera Biopharmaceuticals, Limerick BioPharma, Effector Therapeutics, Cambrios Technologies, Sienna Biopharmaceuticals, Beam Therapeutics, . Over time, Dave Maki has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Dave Maki is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Genetics, Women Founded, Life Science, Artificial Intelligence (AI), Biotechnology, Market Research, Electronic Health Records (EHR), Genomics, Health and Hospital Services, Digital Health, Medical, Therapeutics, Pharmaceuticals may find it worthwhile to explore potential connections with Dave Maki, as their portfolio suggests a familiarity and interest in this area.

Understanding Dave Maki’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.